Premium Relugolix API in Pakistan: Reliable Raw Material Supply for Pharmaceutical Formulators

Product Name: Relugolix (Active Pharmaceutical Ingredient)

Supplier / Distributor: Morgan

Therapeutic Category: Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist

Indications: Advanced Prostate Cancer, Uterine Fibroids, Endometriosis

Compliance Notice: This technical data page is strictly for B2B pharmaceutical manufacturers, contract manufacturing organizations (CMOs), and analytical laboratories. The Relugolix distributed by Morgan is a highly purified Active Pharmaceutical Ingredient (API) intended exclusively for commercial formulation and laboratory R&D. It is not a finished drug product.

About Morgan: Morgan Chemicals (Pvt.) Ltd. is a pharmaceutical raw material trading and distribution company. We source APIs from DRAP-registered and internationally certified manufacturers and supply exclusively to licensed pharmaceutical companies, CMOs, and research facilities. We do not manufacture APIs or sell finished medicines.

Product Overview and Mechanism of Action

Relugolix is a highly potent, orally active, non-peptide small-molecule Active Pharmaceutical Ingredient (API). Within endocrine and oncological pharmacology, it is classified as a targeted gonadotropin-releasing hormone (GnRH) receptor antagonist. For pharmaceutical formulation scientists, this API represents a critical component in the development of modern hormone-suppression therapeutics.

Unlike legacy GnRH agonists (such as leuprolide) which initially stimulate the receptor and cause a temporary surge in hormone levels, Relugolix operates through direct, competitive antagonism. It binds specifically to GnRH receptors located in the anterior pituitary gland.

By blocking these receptors, the API immediately halts the downstream signaling cascade, resulting in a rapid decrease in the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In male patients, this sharply suppresses the testicular production of testosterone to castrate levels, which is the primary therapeutic goal in managing advanced prostate cancer. In female patients, the suppression of ovarian estradiol and progesterone makes it highly effective in combined therapies for uterine fibroids and endometriosis.

In commercial manufacturing, this active ingredient is typically formulated into 120 mg oral solid tablets for oncology indications, or in lower-dose (40 mg) fixed-dose combinations for women's health indications.

Sourcing Relugolix in Pakistan: Morgan’s Supply Network

Developing complex oncological and endocrine formulations requires a secure, traceable, and highly consistent raw material pipeline. Procuring advanced hormonal APIs for commercial manufacturing frequently involves navigating extended lead times, stringent customs documentation, and highly complex regulatory compliance. Sourcing Relugolix Pakistan through Morgan’s localized distribution network mitigates these complex supply chain risks.

Morgan sources commercial-scale and pilot-scale quantities from global manufacturing partners operating in strict adherence to ICH Q7 Good Manufacturing Practice (GMP) guidelines. Partnering with Morgan as your primary supply vendor secures several operational provisions for your manufacturing facility:

• DRAP Submission Assistance: Morgan coordinates with DRAP-registered API manufacturers to obtain and forward the necessary compliance documentation on your behalf. This includes the open part of the Drug Master File (DMF), comprehensive impurity profiles, and accelerated stability data to strictly support your Drug Regulatory Authority of Pakistan (DRAP) dossier submissions.
• Supply Chain Stability: Our localized API inventory management eliminates international transit variables. Whether you require a standard pilot batch or are scaling up a high-volume Relugolix api Pakistan procurement order, we help ensure that your commercial batch schedules are met without costly line stoppages.
• Batch-to-Batch Uniformity: Every shipment coordinated by Morgan includes a detailed Certificate of Analysis (CoA) issued by the original manufacturer. We ensure our supplied batches maintain consistent chemical purity, controlled moisture limits, and a precise particle size distribution (PSD) for predictable behavior during dry blending, wet granulation, and tablet compression.

Technical Specifications for QA & R&D

The Relugolix API supplied by Morgan undergoes exacting analytical testing at the source to meet current international pharmacopeial standards.

• Chemical Name: 1-[4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea
• CAS Number: 737789-87-6
• Appearance: White to off-white crystalline solid powder
• Molecular Formula: C29H27F2N7O5S
• Molecular Weight: 623.6 g/mol
• Assay / Purity (HPLC): ≥ 99.0%
• Solubility Profile: Detailed solubility parameters across standard organic solvents and aqueous buffers are documented in the technical data sheet to assist your analytical R&D teams with dissolution profiling and pre-formulation stability studies.

Manufacturing and Handling Guidelines for Formulators

Relugolix is a highly potent endocrine-disrupting pharmacological compound. Facilities processing this API must enforce stringent occupational exposure limits (OEL) to protect personnel on the manufacturing floor.

• Storage Conditions: Store the raw API powder in securely closed, light-resistant containers. Maintain climate-controlled conditions as specified by the batch protocol (typically controlled room temperature, strictly protected from excessive heat and humidity) to prevent chemical degradation.
• Occupational Safety: Personnel handling the pure API powder must follow advanced industrial containment protocols. Due to its mechanism of action, pregnant women or women of childbearing potential must not handle this API. Processing requires appropriate Personal Protective Equipment (PPE), including P3/N95 industrial dust masks or powered air-purifying respirators (PAPR), chemical-resistant nitrile gloves, and full protective facility garments. Dispensing, micronization, milling, and blending stages must be executed within localized exhaust ventilation systems or dedicated negative-pressure containment isolators.

Distributor Disclaimer: Morgan Chemicals is a pharmaceutical raw material trading and distribution company. This API is sourced from DRAP-registered, GMP-certified manufacturing partners. Morgan Chemicals does not manufacture APIs, does not hold DRAP manufacturing registration, and does not sell finished medicines. This product is supplied exclusively to licensed pharmaceutical companies, CMOs, and research facilities in Pakistan — not for individual or consumer sale.